公开(公告)号：US20110182894A1

公开(公告)日：2011-07-28

申请号：US13044918

申请日：2011-03-10

Applicant: Hermann Gram ,  Franco E. Di Padova

Inventor： Hermann Gram ,  Franco E. Di Padova

IPC: A61K39/395 ,  A61P3/10

CPC classification number: C07K16/245 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/565

Abstract: An IL-1β binding molecule, in particular an antibody to human IL-1β, especially a human antibody to human IL-1β is provided, wherein the CDRs of the heavy and light chains have amino acid sequences as defined, for use in the treatment of an IL-1 mediated disease or disorder, e.g. osteoarthritis, osteoporosis and other inflammatory arthritides.

Abstract translation: IL-1和bgr 特别是对人IL-1和bgr的抗体，特别是人IL-1和bgr的人抗体; 其中重链和轻链的CDR具有如所定义的氨基酸序列，用于治疗IL-1介导的疾病或病症，例如， 骨关节炎，骨质疏松症和其他炎症性关节炎。

公开(公告)号：US20100166750A1

公开(公告)日：2010-07-01

申请号：US12601280

申请日：2008-05-28

Applicant: Hermann Gram ,  Thomas Jung

Inventor： Hermann Gram ,  Thomas Jung

IPC: A61K39/395 ,  A61P19/02

CPC classification number: C07K16/245 ,  A61K39/3955 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

Abstract: This invention relates to a novel use of IL-1β-ligand/IL-1 receptor disrupting compounds (herein referred to as “IL-1beta Compounds”); such as small molecular compounds disrupting IL-1β ligand-IL-1 receptor interaction, IL-1β antibodies or IL-1 receptor antibodies, e.g. IL-1β binding molecules described herein, e.g. antibodies disclosed herein, e.g. IL-1β binding compounds or IL-1 receptor binding compounds, and/or RNA compounds decreasing either IL-1β ligands or IL-1 receptor protein levels, in the treatment and/or prevention of auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome and to methods of treating and/or preventing auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome, in mammals, particularly humans.

Abstract translation: 本发明涉及IL-1和bIG - 配体/ IL-1受体破坏化合物（本文中称为“IL-1β化合物”）的新用途。 例如破坏IL-1和bgr的小分子化合物; 配体-IL-1受体相互作用，IL-1和bgr; 抗体或IL-1受体抗体。 IL-1和bgr 本文所述的结合分子，例如。 本文公开的抗体，例如 IL-1和bgr 结合化合物或IL-1受体结合化合物，和/或降低IL-1和bgr的RNA化合物; 配体或IL-1受体蛋白水平，用于治疗和/或预防自身炎症综合征，例如， 少年类风湿性关节炎或成人类风湿性关节炎综合征以及治疗和/或预防自身炎症综合征的方法，例如， 少年类风湿关节炎或成人类风湿关节炎综合征，在哺乳动物，特别是人类。

公开(公告)号：US20090081732A1

公开(公告)日：2009-03-26

申请号：US12238502

申请日：2008-09-26

Applicant: Hermann Gram ,  Franco E. Di Padova

Inventor： Hermann Gram ,  Franco E. Di Padova

IPC: C12P21/02 ,  C07K16/24 ,  C07H21/00 ,  A61K39/395 ,  C12N15/63

CPC classification number: C07K16/245 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/34

Abstract: An IL-1β binding molecule, in particular an antibody to human IL-1β, especially a human antibody to human IL-1β is provided, wherein the CDRs of the heavy and light chains have amino acid sequences as defined, for use in the treatment of an IL-1 mediated disease or disorder, e.g. osteoarthritis, osteoporosis and other inflammatory arthritides.

公开(公告)号：US20080318838A1

公开(公告)日：2008-12-25

申请号：US12169134

申请日：2008-07-08

Applicant: Wilfried Bauer ,  Robin Breckenridge ,  Francois Cardinaux ,  Frank Gombert ,  Hermann Gram ,  Paul Ramage ,  Helmut Schneider ,  Rudolf Waelchli ,  Rainer Albert ,  Ian Lewis

Inventor： Wilfried Bauer ,  Robin Breckenridge ,  Francois Cardinaux ,  Frank Gombert ,  Hermann Gram ,  Paul Ramage ,  Helmut Schneider ,  Rudolf Waelchli ,  Rainer Albert ,  Ian Lewis

IPC: A61K38/00 ,  C07K7/00 ,  C12P21/04 ,  C12N15/11 ,  A61P19/00 ,  C12N15/00 ,  C12N1/20

CPC classification number: C07K14/005 ,  A61K38/00 ,  C07K14/635 ,  C07K2319/00 ,  C07K2319/50 ,  C07K2319/75 ,  C12N2795/10222

Abstract: PTH compounds having PTH-like activity and comprising at least one modification, said modification being either 1. at least one radical selected from a L- or D-α-amino acid, C2-6alcoxycarbonyl and optionally substituted C1-8alkyl, C2-8alkenyl, C2-8alkynyl, aralkyl, aralkenyl or C3-6cycloalkyl-C1-4alkyl and attached to the terminal amino group of the PTH compound, and/or at least one radical selected from C2-6alcoxycarbonyl and optionally substituted C1-8alkyl, C2-8alkenyl, C2-8alkynyl, aralkyl, aralkenyl or C3-6cycloalkyl-C1-4alkyl and attached to one or more side chain amino groups of the PTH compound, or 2. at least one α-amino acid unit in the positions 1 to 38 of a naturally occurring PTH sequence being replaced by a natural or unnatural amino acid unit optionally in protected form, whereby the α-amino acid units present in positions 1 and 2 at the amino terminus of the PTH sequence may be replaced by a pseudo-peptide, or a combination of such modifications, in free form or in salt form, have pharmacological activity, e.g. for preventing or treating all bone conditions which are associated with increased calcium depletion or resorption or in which calcium fixation in the bone is desirable.

Abstract translation: 具有PTH样活性并且包含至少一个修饰的PTH化合物，所述修饰是1.至少一个选自L-或D-α-氨基酸，C2-6羰基和任选取代的C 1-8烷基的基团，C 2-8烯基 ，C 2-8炔基，芳烷基，芳烯基或C 3-6环烷基-C 1-4烷基，并且连接到PTH化合物的末端氨基，和/或至少一个选自C 2-6烷氧基羰基和任选取代的C 1-8烷基基团，C 2-8烯基 ，C 2-8炔基，芳烷基，芳烯基或C 3-6环烷基-C 1-4烷基，并且连接到PTH化合物的一个或多个侧链氨基，或2个至少一个α-氨基酸单元的位置1至38 天然存在的PTH序列被任选以保护形式的天然或非天然氨基酸单元替代，由此存在于PTH序列的氨基末端的位置1和2中的α-氨基酸单元可被假肽替代，或 这些修改的组合，免费的 m或盐形式，具有药理活性，例如。 用于预防或治疗与增加的钙耗竭或吸收相关的所有骨骼状况或其中期望骨中的钙固定。

公开(公告)号：US20080286266A1

公开(公告)日：2008-11-20

申请号：US12090490

申请日：2006-10-24

Applicant: Phil Lowe ,  Hermann Gram ,  Thomas Jung ,  Timothy Wright ,  Trevor Mundel

Inventor： Phil Lowe ,  Hermann Gram ,  Thomas Jung ,  Timothy Wright ,  Trevor Mundel

IPC: A61K39/395 ,  A61P29/00

CPC classification number: C07K16/245 ,  A61K39/3955 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

Abstract: This invention relates to a novel use of IL-1β-ligand/IL-1 receptor disrupting compounds (herein referred to as “IL-1beta Compounds”); such as small molecular compounds disrupting IL-1β ligand-IL-1 receptor interaction, IL-1β antibodies or IL-1 receptor antibodies, e.g. IL-1β binding molecules described herein, e.g. antibodies disclosed herein, e.g. IL-1β binding compounds or IL-1 receptor binding compounds, and/or RNA compounds decreasing either IL-1β ligands or IL-1 receptor protein levels, in the treatment and/or prevention of auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome and to methods of treating and/or preventing auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome, in mammals, particularly humans.

Abstract translation: 本发明涉及IL-1β-配体/ IL-1受体破坏性化合物（本文称为“IL-1β化合物”）的新用途。 例如破坏IL-1β配体-IL-1受体相互作用的小分子化合物，IL-1β抗体或IL-1受体抗体。 本文所述的IL-1β结合分子，例如 本文公开的抗体，例如 IL-1β结合化合物或IL-1受体结合化合物和/或降低IL-1β配体或IL-1受体蛋白水平的RNA化合物在治疗和/或预防自身炎症综合征中的应用。 少年类风湿性关节炎或成人类风湿性关节炎综合征以及治疗和/或预防自身炎症综合征的方法，例如， 少年类风湿关节炎或成人类风湿关节炎综合征，在哺乳动物，特别是人类。